Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced that 15 abstracts featuring clinical and
translational data from its oncology and rare genetic diseases
programs will be presented at the American Society of Hematology
(ASH) Annual Meeting being held December 7-10, 2019 in Orlando.
The accepted abstracts are listed below and are available online
on the ASH conference website:
https://ash.confex.com/ash/2019/webprogram/start.html.
Oral Presentations
Abstract #541: Complex Polyclonal Resistance
Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or
Refractory Acute Myeloid Leukemia Revealed By Single Cell
Sequencing AnalysesDate & Time: Monday,
December 9, 2019 at 7:00 a.m. ETOral Abstract
Session: 617. Acute Myeloid Leukemia: Biology,
Cytogenetics, and Molecular Markers in Diagnosis and Prognosis:
Single-Cell and Clonal Approaches to Treatment Resistance in
AMLLocation: Orange County Convention Center,
Valencia A (W415A)Presenter: Hongfang Wang, Ph.D.,
Agios Pharmaceuticals
Abstract #545: Molecular Mechanisms Mediating
Relapse Following Ivosidenib Monotherapy in Patients with
IDH1-Mutant Relapsed or Refractory Acute Myeloid
LeukemiaDate & Time: Monday, December 9, 2019
at 8:00 a.m. ETOral Abstract Session: 617. Acute
Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in
Diagnosis and Prognosis: Single-Cell and Clonal Approaches to
Treatment Resistance in AMLLocation: Orange County
Convention Center, Valencia A (W415A)Presenter:
Sung Choe, Ph.D., Agios Pharmaceuticals
Abstract #643: Enasidenib Plus Azacitidine
Significantly Improves Complete Remission and Overall Response
Compared with Azacitidine Alone in Patients with Newly Diagnosed
Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2)
Mutations: Interim Phase II Results from an Ongoing, Randomized
StudyDate & Time: Monday, December 9, 2019 at
10:30 a.m. ETOral Abstract Session: 613. Acute
Myeloid Leukemia: Clinical Studies: Non-Intensive
TherapyLocation: Orange County Convention Center,
Valencia A (W415A)Presenter: Courtney DiNardo,
M.D., University of Texas MD Anderson Cancer Center
Poster Presentations
Abstract #2175: Comorbidities and Complications
in Adults with Pyruvate Kinase DeficiencyPoster Session
Date & Time: Saturday, December 7, 2019 from 5:30-7:30
p.m. ETPoster Session: 904. Outcomes Research –
Non-Malignant Conditions: Poster II
Abstract #1570: Hematologic Malignancies
Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine
Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate
Dehydrogenase in Phase 1 Clinical TrialsPoster Session Date
& Time: Saturday, December 7, 2019 from 5:30-7:30 p.m.
ETPoster Session: 625. Lymphoma: Pre-Clinical –
Chemotherapy and Biologic Agents: Poster I
Abstract #1286: AG-636 for the Treatment of
Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical
StudyPoster Session Date & Time: Saturday,
December 7, 2019 from 5:30-7:30 p.m. ETPoster
Session: 605. Molecular Pharmacology, Drug Resistance –
Lymphoid and Other Diseases: Poster I
Abstract #2223: An Ongoing Global,
Longitudinal, Observational Study of Patients with Pyruvate Kinase
Deficiency: The PEAK RegistryPoster Session Date &
Time: Sunday, December 8, 2019 from 6:00-8:00 p.m.
ETPoster Session: 101. Red Cells and
Erythropoiesis, Structure and Function, Metabolism, and Survival,
Excluding Iron: Poster II
Abstract #2249: Mitapivat (AG-348), an Oral
PK-R Activator, in Adults with Non-Transfusion Dependent
Thalassemia: A Phase 2, Open-Label, Multicenter Study in
ProgressPoster Session Date & Time: Sunday,
December 8, 2019 from 6:00-8:00 p.m. ETPoster
Session: 112. Thalassemia and Globin Gene Regulation:
Poster II
Abstract #3447: Development of Patient-Reported
Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate
Kinase DeficiencyPoster Session Date & Time:
Sunday, December 8, 2019 from 6:00-8:00 p.m. ETPoster
Session: 904. Outcomes Research – Non-Malignant
Conditions: Poster II
Abstract #2593: AGILE: A Phase 3, Multicenter,
Double‐Blind, Randomized, Placebo‐Controlled Study of Ivosidenib in
Combination with Azacitidine in Adult Patients with Previously
Untreated Acute Myeloid Leukemia with an IDH1
MutationPoster Session Date & Time: Sunday,
December 8, 2019 from 6:00-8:00 p.m. ETPoster
Session: 613. Acute Myeloid Leukemia: Clinical Studies:
Poster II
Abstract #2706: High Rate of IDH1 Mutation
Clearance and Measurable Residual Disease Negativity in Patients
with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated
with Ivosidenib (AG-120) and AzacitidinePoster Session Date
& Time: Sunday, December 8, 2019 from 6:00-8:00 p.m.
ETPoster Session: 617. Acute Myeloid Leukemia:
Biology, Cytogenetics, and Molecular Markers in Diagnosis and
Prognosis: Poster II
Abstract #3512: Long-Term Safety and Efficacy
of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients
with Pyruvate Kinase Deficiency: The DRIVE PK StudyPoster
Session Date & Time: Monday, December 9, 2019 from
6:00-8:00 p.m. ETPoster Session: 101. Red Cells
and Erythropoiesis, Structure and Function, Metabolism, and
Survival, Excluding Iron: Poster III
Abstract #3526: Mitapivat (AG-348) in Adults
with Pyruvate Kinase Deficiency Who Are Regularly Transfused: A
Phase 3, Open-Label, Multicenter, Study (ACTIVATE-T) in
ProgressPoster Session Date & Time: Monday,
December 9, 2019 from 6:00-8:00 p.m. ETPoster
Session: 101. Red Cells and Erythropoiesis, Structure and
Function, Metabolism, and Survival, Excluding Iron: Poster III
Abstract #3513: Prevalence of Pyruvate Kinase
Deficiency: A Systematic Literature ReviewPoster Session
Date & Time: Monday, December 9, 2019 from 6:00-8:00
p.m. ETPoster Session: 101. Red Cells and
Erythropoiesis, Structure and Function, Metabolism, and Survival,
Excluding Iron: Poster III
Abstract #4254: Ivosidenib (AG-120) in Patients
with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome:
Updated Enrollment of a Phase 1 Dose Escalation and Expansion
StudyPoster Session Date & Time: Monday,
December 9, 2019 from 6:00-8:00 p.m. ETPoster
Session: 637. Myelodysplastic Syndromes – Clinical
Studies: Poster III
Event and Webcast InformationAgios will host an
investor event on December 9, 2019 at 8:00 p.m. ET in Orlando to
review the data from the company's oncology and rare genetic
diseases programs. The event will be webcast live and can be
accessed under "Events & Presentations" in the Investors
section of the company's website at www.agios.com. The archived
webcast will be available on the company's website beginning
approximately two hours after the event.
About Agios Agios is focused on discovering and
developing novel investigational medicines to treat cancer and rare
genetic diseases through scientific leadership in the field of
cellular metabolism and adjacent areas of biology. In addition to
an active research and discovery pipeline across both therapeutic
areas, Agios has two approved oncology precision medicines and
multiple first-in-class investigational therapies in clinical
and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website
at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of TIBSOVO® (ivosidenib) and
mitapivat; Agios’ plans regarding future data presentations; and
the potential benefit of its strategic plans and focus. The words
“anticipate,” “expect,” “intend,” “potential,” “milestone,” “goal,”
“will,” “on track,” “upcoming,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios' current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
or its collaborators is developing will successfully commence or
complete necessary preclinical and clinical development phases, or
that development of any of Agios' product candidates will
successfully continue. Moreover, there can be no guarantee that the
two approved oncology precision medicines being commercialized by
Agios and its collaborators will receive commercial acceptance.
There can be no guarantee that any positive developments in Agios'
business will result in stock price appreciation. Management's
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties
relating to a number of other important factors, including: Agios'
results of clinical trials and preclinical studies, including
subsequent analysis of existing data and new data received from
ongoing and future studies; the content and timing of decisions
made by the U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios' ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media ContactHolly Manning,
617-844-6630Associate Director, Investor
RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2023 to Mar 2024